Assessing reliability and validity of a functional outcome measure for adolescents with hypermobility spectrum disorder

Abstract

Purpose

To determine the reliability and validity of the upper extremity function and pain scales of the Pediatric Outcomes Data Collecton Instrument (PODCI UEF and PODCI P) as an outcome measure in adolescents with Hypermobility Spectrum Disorder (HSDs).

Materials and methods

An observational study using a cross-section design was conducted. A convenience sample of 83 adolescents (age 11–18 years) with HSDs were recruited. Test-retest reliability of the PODCI UEF and PODCI P was examined using Lin’s concordance correlation coefficient (ρ_c). Concurrent validity was established by comparing the PODCI UEF to the PROMIS Pediatric Upper Extremity-Short Form (PROMIS PUE-SF) and comparing the PODCI P to Numeric Rating Scale (NRS) using Spearman rho correlations.

Results

There was high test-retest reliability for the PODCI UEF, ρ_c = 0.81 (p < 0.001) and moderate test-retest reliability for the PODCI P, ρ_c = 0.68 (p < 0.001). There was a strong correlation between the PODCI UEF and the PROMIS PUE-SF, r_s = 0.80 (p < 0.001) and a moderate inverse relationship r_s = −0.73 (p < 0.001) between PODCI P and NRS scores (n = 150).

Conclusion

The PODCI UEF and PODCI P may be a valid and reliable outcome measure in adolescents with HSDs.

Implications for rehabilitation

• Adolescents with joint hypermobility can have chronic pain, fatigue, and decreased participation in daily activities.

• Clinical use of valid and reliable outcome measures to measure change may assist in planning care and identifying best practice for the management of HSDs.

• The PODCI was designed to be used as an outcome measure for chronic musculoskeletal conditions and has demonstrated test-retest reliability, validity, and responsiveness to change in other pediatric populations.

• The PODCI may be a valid and reliable outcome measure in adolescents with HSDs.

Keywords:

• PODCI
• pain
• upper extremity function
• PROMIS
• pediatric

Disclosure statement

The authors report no conflicts of interest or financial disclosures.

Ethical approval

The study was approved by the Institutional Review Board (IRB), IRB00000231.